Maze Therapeutics, Inc.
MAZE
$25.56
-$0.87-3.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -88.06% | -- | -100.00% | -98.48% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.06% | -- | -100.00% | -98.48% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -88.06% | -- | -100.00% | -98.48% | -- |
| SG&A Expenses | 38.90% | 30.41% | 21.45% | 23.20% | 13.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.33% | 30.01% | 30.34% | 26.14% | 15.65% |
| Operating Income | -367.04% | -348.15% | -309.41% | -298.90% | 149.49% |
| Income Before Tax | -330.73% | -345.53% | -323.02% | -313.03% | 149.01% |
| Income Tax Expenses | -- | -- | -119.00% | -132.10% | -- |
| Earnings from Continuing Operations | -335.93% | -351.04% | -328.36% | -318.68% | 147.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -335.93% | -351.04% | -328.36% | -318.68% | 147.93% |
| EBIT | -367.04% | -348.15% | -309.41% | -298.90% | 149.49% |
| EBITDA | -347.77% | -330.76% | -294.54% | -283.46% | 154.63% |
| EPS Basic | -241.08% | -318.12% | 42.56% | -67.81% | 105.18% |
| Normalized Basic EPS | -106.90% | -112.46% | -151.33% | -187.04% | 184.54% |
| EPS Diluted | 63.67% | 55.82% | 70.34% | 14.48% | 79.86% |
| Normalized Diluted EPS | -173.01% | 55.71% | -157.86% | -228.47% | 107.99% |
| Average Basic Shares Outstanding | 448.75% | 1,690.48% | 1,174.32% | 725.32% | 288.86% |
| Average Diluted Shares Outstanding | 404.85% | 1,250.76% | 858.45% | 519.04% | 322.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |